1
40
1
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
Citation List Month
November 2017 List
Notes
<p>Franco, Jose Francisco da Silva<br />El Dib, Regina<br />Agarwal, Arnav<br />Soares, Diogo<br />Milhan, Noala Vicensoto Moreira<br />Albano, Lilian Maria Jose<br />Kim, Chong Ae<br />Journal Article<br />Japan<br />Intractable Rare Dis Res. 2017 Aug;6(3):183-190. doi: 10.5582/irdr.2017.01036.</p>
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Mucopolysaccharidosis type I, II and VI and response to enzyme replacement therapy: Results from a single-center case series study
Publisher
An entity responsible for making the resource available
Intractable Rare Dis Res
Date
A point or period of time associated with an event in the lifecycle of the resource
2017
Subject
The topic of the resource
Glycosaminoglycans; Lysosomal Storage Disorders; Prognosis; Treatment
Creator
An entity primarily responsible for making the resource
Franco Jfds; El Dib R; Agarwal A; Soares D; Milhan NVM; Albano LMJ; Kim CA
Description
An account of the resource
Mucopolysaccharidoses (MPS) types I, II and VI are associated with deficiencies in alpha-L-iduronidase, iduronate-2-sulfatase and N-acetylgalactosamine-4-sulfatase, respectively, and generally involve progressive and multi-systemic clinical manifestations. Enzyme replacement therapy (ERT) appears to be reasonably well tolerated. The aim of this study was to examine clinical and diagnostic findings of a series of pediatric and adult MPS patients, and assess the safety and efficacy of ERT in children and adults with MPS type I, II and VI. Pediatric and adult patients were treated weekly with 1 mg/kg recombinant human N-acetylgalactosamine-4-sulphatase (rhASB), 0.45 mg/kg alpha-L-iduronidase, or 0.5 mg/kg iduronate-2-sulfatase. Clinical and biochemical parameters with ERT were evaluated for a mean duration of 5 years. Mantel-Haenszel risk ratios and associated 95% confidence intervals (CIs) were calculated for rates of death among different types of enzyme replacement therapies (ERTs). Twenty-seven patients (mean ages pediatric: 6.8 years; adult: 29 years) were included. ERT was found to be consistently well tolerated and effective in attenuating symptoms, but did not prevent the progression of the disease or reduce mortality rates. Our findings demonstrated that early diagnosis and initiation of ERT are critical for improvements in patient-important outcomes and quality of life, although disease progression and mortality rates remain high.
Identifier
An unambiguous reference to the resource within a given context
10.5582/irdr.2017.01036
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. PedPalASCNET does not hold any rights over the resource listed here. All rights are retained by the journal listed under publisher and/or the creator(s).
2017
Agarwal A
Albano LMJ
El Dib R
Franco Jfds
Glycosaminoglycans
Intractable Rare Dis Res
Kim CA
Lysosomal Storage Disorders
Milhan NVM
November 2017 List
Prognosis
Soares D
Treatment